Bloodstream Infection Testing Market growing at a CAGR of 4.5% from 2023 to 2031

Key Market Overview

Consegic Business Intelligence analyzes that the bloodstream infection testing market is predicted to grow at a compound annual growth rate of 4.5% from 2023 to 2031 and is expected to reach USD 4,860.22 million in 2031 and 3,415.65 million in 2023 which was valued at USD 3,283.63 million in 2022.

The report highlights the increasing incidences of bloodstream infections is driving the market growth, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the bloodstream infection testing market.

Global Bloodstream Infection Testing Market By Overview

The bloodstream infection testing market is bifurcated into product type, technology and end user. Based on the product type, the market is segmented into based on consumables, instruments, and software. In 2022, the consumables segment dominate the overall bloodstream infection testing market. Based on the technology, the market is segmented into conventional, PCR methods, nucleic acid testing, mass spectroscopy, and POC testing. In 2022, the conventional segment dominate the overall bloodstream infection testing market. Based on end user, the market is segmented into hospitals, diagnostic centers, research institutes, and others. In 2022, the hospitals segment dominate the overall bloodstream infection testing market.

Get Free Sample

Market Dynamics

Driver:

Increasing incidences of bloodstream infections across the globe.
Growing awareness of the importance of early detection and treatment of bloodstream infection

Restraints:

High maintenance cost and prices of devices and consumables

Market Segmentation:

Report Attributes	Report Details
By Product Type	Consumables, Instruments, and Software
By Technology	Conventional, PCR Methods, Nucleic Acid Testing, Mass Spectroscopy, and POC Testing
By End User	Hospitals, Diagnostic Centers, Research Institutes, and Others

Competitive Landscape :

The market is dominated by certain major companies such as Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Abbott, and BioMeruix which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the bloodstream infection testing market is expected to witness substantial growth in the coming years due to in growing government initiatives for healthcare research and development activities in key regions such as North America, Asia Pacific, and others.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Abbott
BioMeruix
Cepheid
Luminex Corporation.
Accelerate Diagnostics
Bruker
HiMedia Laboatories
Diasorin

Global Bloodstream Infection Testing Market growing at a CAGR of 4.5% from 2023 to 2031